| Domain | Key evidence-backed finding | Suggested ontology identifiers/terms | Evidence scope/limitations |
|---|---|---|---|
| Disease identity | **Choriocarcinoma** is a malignant trophoblastic neoplasm; MONDO association available as **MONDO:0005207**. In clinical practice, reports should distinguish **gestational choriocarcinoma** from **nongestational germ-cell choriocarcinoma**, because etiology, molecular origin, and treatment context differ (pqac-00000000, pqac-00000013, pqac-00000026) | MONDO:0005207; suggested terms: choriocarcinoma, gestational choriocarcinoma, nongestational choriocarcinoma, uterine corpus choriocarcinoma, ovarian choriocarcinoma, testicular choriocarcinoma | MONDO link is supported; subtype ontologies beyond MONDO:0005207 were not comprehensively validated here. Literature retrieved was much richer for gestational disease than for nongestational germ-cell disease. |
| Major subtypes / taxonomy | Major clinically relevant groupings: **gestational choriocarcinoma** (usually postmolar but may follow any pregnancy), **nongestational ovarian/testicular/extragonadal choriocarcinoma** as a germ-cell tumor component, and **precursor hydatidiform mole** / postmolar GTN, which must not be conflated with frank choriocarcinoma (pqac-00000013, pqac-00000021, pqac-00000026) | Suggested disease terms: gestational trophoblastic neoplasia (GTN), hydatidiform mole, complete hydatidiform mole, partial hydatidiform mole, invasive mole, choriocarcinoma | Much of the molecular literature concerns precursor moles or broader GTN rather than pure choriocarcinoma. Nongestational biology is underrepresented in the retrieved evidence. |
| Etiology / causal factors | Gestational disease arises from abnormal trophoblastic proliferation after pregnancy; complete hydatidiform moles are typically androgenetic and carry higher risk of progression to invasive mole/choriocarcinoma than partial moles. Recurrent molar disease is associated with maternal-effect/imprinting genes such as **NLRP7** and **KHDC3L** in precursor disease (pqac-00000013, pqac-00000020, pqac-00000021) | Suggested terms: abnormal fertilization, genomic imprinting defect, androgenetic conceptus, trophoblast neoplasm | Strongest causal evidence is for precursor villous disease, not for a single universal driver mutation of choriocarcinoma itself. |
| Risk factors | Higher GTD incidence/risk is reported at maternal age extremes (10–19 and 40–54 years), prior molar pregnancy, and ethnicity/geography differences; Asian women have about double the incidence reported for women of Caucasian descent in the cited guideline, and Black US women are overrepresented in some registers (pqac-00000013, pqac-00000026) | Suggested exposure/risk terms: advanced maternal age, teenage pregnancy, prior molar pregnancy, Asian ancestry | Retrieved evidence is disease-group level for GTD/GTN, not choriocarcinoma-only risk quantification. Protective factors were not well established in retrieved sources. |
| Epidemiology | In highly developed countries, hydatidiform mole prevalence was cited as **1 per 591 pregnancies** and GTD prevalence **1 per 714 live births**; Dutch population incidence over 20 years was **1.67 cases/1000 births/year** for GTD (pqac-00000013) | Suggested epidemiology terms: incidence, prevalence, reproductive-age female predominance | These are GTD-level figures, not choriocarcinoma-specific incidence. Choriocarcinoma is rarer than GTD overall. |
| Core phenotypes / symptoms | Common clinical manifestations across GTN/choriocarcinoma include abnormal vaginal bleeding, elevated/plateauing/rising **β-hCG**, metastatic symptoms, and hemorrhage from tumor sites; brain, liver, and lung metastases are clinically important in high-risk disease (pqac-00000015, pqac-00000016, pqac-00000026) | Suggested HPO terms: **Abnormal uterine bleeding**, **Elevated circulating human chorionic gonadotropin**, **Pulmonary metastases**, **Brain metastases**, **Liver metastases**, **Anemia**, **Hemorrhage** | Direct HPO numeric IDs were not validated here; terms are suggested labels only. Evidence is strongest for GTN/high-risk cohorts rather than phenotype frequencies specific to choriocarcinoma. |
| Anatomy affected | Primary organ is typically **uterus** in gestational choriocarcinoma; metastatic evaluation routinely targets **lung**, **brain**, **liver**, abdomen/pelvis, and genital tract structures (pqac-00000015, pqac-00000026) | Suggested UBERON terms: uterus, endometrium, placenta/chorion, lung, brain, liver, vagina, adnexa | UBERON numeric IDs not validated here. Some anatomic staging language is FIGO/TNM rather than ontology-based. |
| Tissue / cell types | Disease involves malignant **trophoblast** lineage cells; trophoblast research models emphasize **cytotrophoblast**, **syncytiotrophoblast**, and **extravillous trophoblast** biology, with markers such as **GATA3**, **TFAP2C**, low HLA class I, and **C19MC** expression in trophoblast stem-cell systems (pqac-00000020, pqac-00000000) | Suggested CL terms: trophoblast cell, cytotrophoblast, syncytiotrophoblast, extravillous trophoblast | CL numeric IDs were not validated. Many model findings come from trophoblast stem-cell or placental systems, not directly from tumor tissue. |
| Histopathology / IHC | Choriocarcinoma belongs to non-villous malignant GTD; in the broader differential, **p57** is useful mainly to distinguish **complete mole** from partial mole/non-molar tissue because p57 is lost in androgenetic CHM and retained in PHM/non-molar gestations. Molecular pathology and IHC are guideline-recommended in GTD workup (pqac-00000013, pqac-00000021) | Suggested pathology terms: p57/CDKN1C immunostain, trophoblastic neoplasm, molecular genotyping, STR analysis, SNP array | p57 is a **precursor-mole differential tool**, not a definitive diagnostic marker for choriocarcinoma itself. Specific choriocarcinoma IHC panels were not comprehensively retrieved. |
| Molecular / genetic features | Recent transcriptomic work comparing complete moles with postmolar choriocarcinoma identified **33 differentially expressed genes** and implicated **TGF-β pathway dysregulation** with strong **SALL4** expression in postmolar choriocarcinoma; Open Targets evidence also links **TP53**, **GATA3**, and **DHFR** to choriocarcinoma-related evidence (pqac-00000000, pqac-00000002) | Suggested gene terms: **SALL4**, **TP53**, **GATA3**, **DHFR**; suggested pathway terms: TGF-beta signaling pathway | Molecular evidence remains sparse and is based on small transcriptomic comparisons and disease-target aggregation; no single recurrent causal mutation was established from retrieved data. |
| Epigenetics / imprinting | Abnormal genomic imprinting is central in precursor molar disease; CHM pathogenesis is linked to androgenesis and loss of maternally expressed **p57/CDKN1C**. Reviews also highlight dysregulated p53/apoptosis pathways, BCL-2/caspases, growth factor receptors, and microRNAs such as **miR-196b** and **miR-21** in GTD/CHM (pqac-00000020, pqac-00000021, pqac-00000022) | Suggested terms: genomic imprinting, DNA methylation abnormality, microRNA dysregulation, loss of maternal allele expression | Most retrieved epigenetic evidence concerns **hydatidiform mole** rather than established choriocarcinoma. Extrapolation should be cautious. |
| Mechanisms / pathophysiology | Proposed mechanisms include dysregulated trophoblast proliferation/invasion, **TGF-β** signaling changes, angiogenesis imbalance, oxidative stress, EMT-related programs, and marked immune-checkpoint biology with frequent **PD-L1** expression in GTN. A 2024 prognostic review cited **PD-L1 expression at 92.3%** in GTN and described **HLA-G** as a biomarker of chemotherapy resistance in gestational choriocarcinoma (pqac-00000002, pqac-00000006, pqac-00000022) | Suggested GO terms: trophoblast cell proliferation, cell migration, cell invasion, epithelial to mesenchymal transition, angiogenesis, response to oxidative stress, immune evasion, TGF-beta receptor signaling pathway, programmed cell death ligand 1 pathway | Mechanistic evidence is mixed across gestational choriocarcinoma, other GTN subtypes, and precursor lesions. GO numeric IDs not validated. |
| Immune biology | GTN demonstrates strong **PD-L1** expression and immune infiltration, providing biologic rationale for checkpoint blockade. Anti-PD-1/PD-L1 therapy has become a salvage standard for multidrug-resistant GTN in some expert settings (pqac-00000006, pqac-00000009, pqac-00000011, pqac-00000016) | Suggested terms: PD-L1 expression, PD-1 checkpoint pathway, tumor-infiltrating lymphocytes, immune checkpoint inhibitor response | Evidence is strongest in refractory GTN cohorts, not frontline choriocarcinoma-only populations. Biomarker predictors of response remain incompletely defined. |
| Diagnostic biomarkers | **Serial serum β-hCG** is central for diagnosis, monitoring, and remission assessment. Postmolar GTN/choriocarcinoma diagnostic criteria include plateau or rise in hCG over specified intervals; after therapy, remission monitoring requires serial negative hCG measurements (pqac-00000004, pqac-00000014, pqac-00000015, pqac-00000023, pqac-00000025) | Suggested LOINC/biomarker terms: serum beta-human chorionic gonadotropin (β-hCG), serial quantitative hCG monitoring | Exact thresholds/definitions vary slightly by guideline/trial. hCG criteria are most validated in postmolar GTN. |
| Diagnostic criteria | Guideline criteria for persistent postmolar villous GTD include: **four or more consecutive hCG values with plateau over ≥3 weeks**, **rise in hCG on 2 consecutive measurements (day 0 and 7)**, or **persistent hCG values over 6 months**; trial eligibility criteria similarly define plateau/rise patterns for GTN (pqac-00000014, pqac-00000023, pqac-00000025) | Suggested terms: FIGO 2000 criteria, postmolar GTN, hCG plateau, hCG rise | These criteria chiefly define postmolar GTN rather than all histologically confirmed choriocarcinoma presentations. |
| Imaging / staging | Recommended staging includes gynecologic exam with palpation, **transvaginal ultrasound**, **CT thorax and abdomen**, and **MRI brain**; **FDG-PET/CT** may be used if metastasis is suspected. Postoperative malignant GTD should also follow current **TNM** classification in addition to FIGO staging (pqac-00000013, pqac-00000015) | Suggested imaging terms: pelvic ultrasound, CT chest, CT abdomen, brain MRI, FDG-PET/CT, TNM stage, FIGO stage | Guidance is strong for gestational trophoblastic neoplasia. Imaging approach for nongestational germ-cell choriocarcinoma may differ by site and oncology service. |
| FIGO stages / risk strata | FIGO stage: **I uterus-confined**, **II genital structures**, **III lungs**, **IV other metastatic sites**. Prognostic score uses age, antecedent pregnancy, interval since pregnancy, pretreatment hCG, metastasis number/site, tumor size, and prior chemotherapy; **0–4 low risk**, **5–6 intermediate risk**, **≥7 high risk** (pqac-00000013, pqac-00000026) | Suggested terms: FIGO stage I-IV, WHO/FIGO prognostic score, low-risk GTN, intermediate-risk GTN, high-risk GTN | Core evidence is GTN-wide. Some centers now debate refinements beyond classic FIGO 2000 scoring. |
| First-line treatment strata | Guideline: low-risk disease typically receives **methotrexate** with folinic/folic acid rescue; methotrexate-resistant cases may switch to **actinomycin-D** or polychemotherapy. For FIGO **5–6**, methotrexate may be used, but **EMA-CO** is recommended when FIGO 5–6 coexists with distant metastases, hCG >411,000 IU/L, or diagnosis of choriocarcinoma (pqac-00000014, pqac-00000026) | Suggested NCIT terms: Methotrexate, Actinomycin D, Folic Acid, EMA-CO regimen | Guidance is primarily for gestational disease. Dose/schedule details may vary among regions and centers. |
| High-risk / metastatic treatment | **EMA-CO** remains standard for high-risk GTN; one 2023 review cited **93% complete remission** with EMA-CO in high-risk GTN and noted ~40% salvage of incomplete responses with platinum-based chemotherapy. Brain-metastatic disease may require higher-dose methotrexate-containing regimens (pqac-00000026) | Suggested NCIT terms: EMA-CO, EMA-EP, EP/EMA, BEP, platinum-based combination chemotherapy | Numbers are from GTN/high-risk reviews, not pure choriocarcinoma-only prospective datasets. |
| Choriocarcinoma-specific treatment note | A recent review citing historical stage-specific outcomes reported **83% cure in stage I choriocarcinoma with single-agent chemotherapy**, with additional remissions after further chemotherapy or surgery; stage II-IV disease required combined surgery and chemotherapy (pqac-00000001, pqac-00000003) | Suggested NCIT terms: single-agent chemotherapy, hysterectomy, metastasectomy, combined modality therapy | Source summarizes older outcome series; exact regimen details and cohort era were not fully resolved from retrieved excerpt. |
| Immunotherapy | Checkpoint inhibitors are a major recent development. Across **133 GTN patients** treated with CPI, **85 achieved complete remission**; among **118 high-risk/relapsed/multidrug-resistant** patients, **77** achieved CR; among **15 low-risk** patients, **8** achieved remission. Pembrolizumab, avelumab, camrelizumab, toripalimab, and combinations with apatinib/chemotherapy are reported (pqac-00000008, pqac-00000012) | Suggested NCIT terms: Pembrolizumab, Avelumab, Camrelizumab, Toripalimab, immune checkpoint inhibitor therapy, anti-PD-1 therapy, anti-PD-L1 therapy | Data are mostly single-arm, retrospective, or case-based, and encompass GTN broadly, including PSTT/ETT and refractory disease. |
| Fertility / follow-up | After chemotherapy completion with undetectable hCG, guideline follow-up is **monthly hCG for 1 year** with **oral hormonal contraception** during that period. Pregnancy after GTD is generally possible; recurrence risk cited as **0.7–2.6% after one prior GTD** and **~10% after two GTDs**; live birth rate cited as **75%** after GTD history (pqac-00000015, pqac-00000016) | Suggested terms: fertility preservation, contraception after GTN, hCG surveillance, pregnancy after GTD | Evidence is GTD-wide, not choriocarcinoma-only. Immunotherapy-era fertility data remain limited. |
| Prognosis | A 2023 review states GTN can achieve **near-100% cure with adequate treatment** and emphasizes markedly reduced mortality over time; high-risk disease still requires urgent multi-agent therapy, and ultra-high-risk/refractory disease remains a challenge (pqac-00000026, pqac-00000011) | Suggested prognostic terms: complete remission, overall survival, relapse, chemotherapy resistance, ultra-high-risk disease | Prognosis is excellent in specialized centers for gestational disease, but not necessarily generalizable to nongestational germ-cell choriocarcinoma. |
| Current real-world trials | Recruiting/active studies include **NCT06028672** (toripalimab + actinomycin-D vs actinomycin-D for FIGO 5–6 GTN), **NCT05139095** (camrelizumab + apatinib + chemotherapy for ultra-high-risk or relapsed high-risk GTN), **NCT05635344** (single-dose neoadjuvant pembrolizumab before second evacuation for low-risk postmolar GTN), and **NCT04562558** (biweekly actinomycin-D vs multiday methotrexate in low-risk GTN) (pqac-00000023, pqac-00000024, pqac-00000025) | Suggested NCIT/clinical trial terms: toripalimab, camrelizumab, apatinib, pembrolizumab, actinomycin-D, methotrexate, neoadjuvant immunotherapy | These studies are GTN-focused and often include but are not limited to choriocarcinoma. Most are not specific to nongestational choriocarcinoma. |
| Model systems | Choriocarcinoma-derived cell lines (**JAR, JEG-3, BeWo**) remain widely used as trophoblast surrogates, but reviews caution they differ substantially from normal trophoblast. Newer **human trophoblast stem cells** and **trophoblast organoids** better recapitulate placental biology; xenograft and germ-cell tumor models exist but incompletely model gestational choriocarcinoma (pqac-00000020) | Suggested model terms: JAR cell line, JEG-3 cell line, BeWo cell line, trophoblast stem cell, trophoblast organoid, xenograft model | Model limitation is important: placental/trophoblast systems are not synonymous with malignant gestational choriocarcinoma, and many animal models do not capture human villous hemochorial placentation. |


*Table: This table condenses the most evidence-supported, ontology-oriented facts for a choriocarcinoma knowledge-base entry. It emphasizes where evidence is strong for gestational trophoblastic neoplasia and where caution is needed when extrapolating to pure choriocarcinoma or nongestational germ-cell disease.*